Let AUTUMN Be
the Start of
Something Better

This clinical study is focused on kidney protection and immune balance for people with primary membranous nephropathy (PMN).

What’s the Purpose of the

AUTUMN Study?

The study aims to evaluate whether the study drug ALXN1920, compared to a placebo, can reduce symptoms in adults with PMN such as:

Excess protein in urine

Swelling

Risk of kidney function decline

Learn More

Can I Participate?

You may be eligible to participate in this study if you:

Are between 18-75 years old

Have been diagnosed with primary membranous nephropathy (PMN)

Have high levels of protein in your urine [about 3.5 grams or more per day]

Are already on or able to receive standard-of-care therapy for PMN

You may not be eligible to participate in this study if you:

Have significant loss of kidney function

Have other kidney diseases or a history of kidney transplant

Other eligibility criteria apply and will be evaluated by a study doctor if you choose to continue with screening for the study.

I'm Interested

Why Should I Join the

AUTUMN Study?

The study drug ALXN1920 aims to more specifically target and block the immune system in addition to currently used immunosuppressive drugs, potentially resulting in less protein in the urine and better kidney function preservation in adults with PMN.

By enrolling in this phase 2a study, you may receive:

Access to expert physicians with experience managing primary membranous nephropathy.

Reimbursements for travel and accommodations, and compensation related to study visits.

The ability to complete some of the study visits at home.

The study drug, ALXN1920, and study-related care are provided at no cost to you.

Insurance is not required to join this study. 

Your participation supports the advancement of treatments for individuals with primary membranous nephropathy. 

See If I Qualify

What Should I Expect?

Fill Out The Questionnaire

1

Submit Online Questionnaire
This questionnaire will ask for your contact information and a few questions about your medical history to determine your eligibility.

Then, select a time for a short phone call with PatientWing. Submitting the questionnaire is voluntary and does not require a commitment to participate in the study.

2

Speak With PatientWing
PatientWing is partnering with Alexion to help identify potential individuals who may be interested in the AUTUMN study.

You will have a short call to answer, additional questions about your medical history and PatientWing will help collect your medical records.

3

Speak With a Research Site
After your conversation with PatientWing, you will meet the study team who will review your medical records.

If the study team thinks you are a good fit, they will schedule a screening visit.

The study team will provide more information during your conversations with them. No question is a bad question so please share your concerns with the team!

4

Study Participation
After you've completed the screening period, the study team will notify you about your eligibility.

If you are enrolled in the study, you should expect the following:
  • You will participate in the study for 38 weeks with at least 29 study visits. Some of these visits have the option of being home visits.
  • You will be randomly assigned to receive an infusion of ALXN1920 or placebo weekly. Each infusion is about 9 minutes long.
  • You will not have to discontinue your current treatments no matter what group you’re assigned.

Frequently Asked Questions

Learn More

How is PatientWing involved in this clinical study process?
We partner with study sponsors to match individuals with clinical studies. Our dedicated team provides clear information about available studies, connects you with research sites, and ensures you have the resources and guidance you need at every step. We are here to support your journey with clinical research!
How will the study drug be taken?
The study drug and/or placebo will be given via a subcutaneous (under the skin) infusion weekly for 26 weeks. The placebo will look and be administered just like the study drug, just containing no active ingredients. You have a 67% chance of receiving the study drug.

In addition to the study drug/placebo, you will also be on other standard-of-care medications that will also help to treat and manage your PMN for the entire duration of the study.
How do I get started?
Complete the questionnaire and enter your information to express interest in the study. You can also email studies@patientwing.com or call 213-459-2979.
Has the study drug been tested before?
Yes, ALXN1920 has previously been tested in preclinical studies and a Phase I clinical study to determine safety.
Can I leave the study at any time?
You’re free to withdraw from the study at any time as study participation is completely voluntary. Withdrawal will not be used against you nor affect your standard medical care in any way. Please contact the study doctor so that they can safely withdraw your participation in the study.
How is the study drug ALXN1920 designed to work?
ALXN1920 is designed to target and block only where it matters - in the kidneys. In PMN, the complement system, a component of the immune system mistakenly attacks the kidneys. This mode of action is unique and different than other treatments that suppress the immune system as whole, and may potentially provide greater benefit in reducing PMN symptoms and protecting kidney function.
How often do I need to visit the research site?
You will have 29 visits with the study team during the study period. Some of those visits have the option of being home visits, if you’re interested. You can speak with the study coordinator to receive more details of which visits can be to the research site during the study period.
Is there a chance I will receive a placebo?
Yes, this study has a 33% chance of receiving a placebo and a 67% chance of receiving ALXN1920.
Will I need to stop my current medications if I join this study?
You may need to continue or stop your current treatments no matter what group you’re assigned to in the study. If you’re not currently on any treatment, you will start standard-of-care treatments prior to the treatment period of the study. The study doctor will share more information during your screening visit.

Learn About
Primary Membranous Nephropathy (PMN)

Primary membranous nephropathy (PMN) is a rare autoimmune disease.
It happens when a component of the immune system, called the complement system, mistakenly attacks the kidney filters. These filters help clean the blood, so when they are damaged, the kidneys cannot work as well.

Fill Out The Questionnaire

When the kidneys are not filtering properly, protein can leak into the urine.

This is called proteinuria. People with PMN may notice foamy urine, swelling in the legs or around the eyes, tiredness, or side effects from medicines that lower the immune system.

Doctors use several tests to diagnose PMN and understand how it is affecting the kidneys:

Blood tests to look for an increase in antibodies called anti-PLA2R, which are found in many people with PMN.

Kidney biopsy to look at the kidney tissue under a microscope and confirm the diagnosis.

Urine tests to check how much protein is leaking into the urine and how well the kidneys are working.

There is currently no medication approved specifically for PMN.

Doctors can help manage symptoms with blood pressure medicines, diuretics, andsometimes with medication thatsuppressyour body’s immune system. Many people also make life style changes, such as lowering salt intake, maintaining a healthy diet, and staying active, to help support kidney health.

Who’s Involved?

About the Sponsor

Alexion's mission is to discover, develop, and deliver innovative therapies that target the underlying cause of diseases, providing hope and a better quality of life for patients who have limited or no treatment options.

About PatientWing

Our mission to bring better treatments to more people faster starts with you. We help sponsors find patients to participate in their clinical studies. With our focus on rare and serious conditions and expertise in navigating the enrollment process, we're here for you every step of the way.

Stay Connected

Receive marketing communications from PatientWing such as patient stories and relevant clinical trial opportunities
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Have Questions?

At PatientWing, we’re here to support you at every step of the study. Fill out the form with any questions.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

studies@patientwing.com

213-459-2979

Privacy Policy

Terms

Can I Participate

What to Expect

FAQs

© 2025 PatientWing. All rights reserved.